Skip to content
Health
Link copied to clipboard
Link copied to clipboard

FDA official: The risk of secondary cancer from CAR-T therapy, pioneered at Penn, is less than feared

Peter Marks, head of the FDA Center for Biologics Evaluation and Research, spoke Friday at an event held by the Sino-American Pharmaceutical Professionals Association — Greater Philadelphia.

Peter Marks, a physician who heads the FDA's Center for Biologics Evaluation and Research, spoke Friday at the @Philly Cell and Gene Therapy Conference in King of Prussia.
Peter Marks, a physician who heads the FDA's Center for Biologics Evaluation and Research, spoke Friday at the @Philly Cell and Gene Therapy Conference in King of Prussia.Read moreHarold Brubaker / Staff
    by Harold Brubaker
    Updated 
    Published